« Back to Record
Citation APA

Curigliano, G., O'Shaughnessy, J., Bidard, F.-C., Casalnuovo, M. L., Kim, S.-B., Tokunaga, E., Aftimos, P., Saura, C., Carey, L. L., Okera, M., Melo, E., Zagouri, F., Magallanes-Maciel, M. E. M., Karadurmus, N., Bahadur, S., Speck, R. R., Wang, X. A., Pradhan, K. K., Macey, J., Kitchen, H., Fairhurst, S., Miller, J., Jhaveri, K. K., & Harbeck, N. (2026). Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial. ESMO Open, 11(4), 106945. doi:10.1016/j.esmoop.2026.106945


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/407722

Curigliano, G., O'Shaughnessy, J., Bidard, F.-C., Casalnuovo, M. L., Kim, S.-B., Tokunaga, E., Aftimos, P., Saura, C., Carey, L. L., Okera, M., Melo, E., Zagouri, F., Magallanes-Maciel, M. E. M., Karadurmus, N., Bahadur, S., Speck, R. R., Wang, X. A., Pradhan, K. K., Macey, J., Kitchen, H., Fairhurst, S., Miller, J., Jhaveri, K. K., & Harbeck, N. (2026). Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial. ESMO Open, 11(4), 106945. doi:10.1016/j.esmoop.2026.106945